106 related articles for article (PubMed ID: 3087373)
21. Pharmacokinetics of mesna and dimesna after simultaneous intravenous bolus and infusion administration in patients undergoing bone marrow transplantation.
el-Yazigi A; Ernst P; al-Rawithi S; Legayada E; Raines DA
J Clin Pharmacol; 1997 Jul; 37(7):618-24. PubMed ID: 9243355
[TBL] [Abstract][Full Text] [Related]
22. Vibrational spectroscopic studies of mesna and dimesna.
Li YS; Wang Y; Church JS; Garzena F; Zhang Z; An D
Spectrochim Acta A Mol Biomol Spectrosc; 2003 Jun; 59(8):1791-8. PubMed ID: 12736065
[TBL] [Abstract][Full Text] [Related]
23. Interaction between mesna and selected transition metals in vitro and in vivo.
Shaw IC; Weeks MS
Arzneimittelforschung; 1986 Jun; 36(6):997-1000. PubMed ID: 3091043
[TBL] [Abstract][Full Text] [Related]
24. [Uroprotection with mesna in the chemotherapy of malignant tumors with oxazaphosphorines. Biometric evaluation of a sequential clinical study].
Schnitker J
Arzneimittelforschung; 1982; 32(10):1334-8. PubMed ID: 6817761
[TBL] [Abstract][Full Text] [Related]
25. Dithio-bis-mercaptoethanesulphonate (DIMESNA) does not prevent cellular damage by metabolites of ifosfamide and cyclophosphamide in LLC-PK1 cells.
Mohrmann M; Ansorge S; Schönfeld B; Brandis M
Pediatr Nephrol; 1994 Aug; 8(4):458-65. PubMed ID: 7524598
[TBL] [Abstract][Full Text] [Related]
26. Modification of the erythrocyte anion carrier by chromate.
Buttner B; Beyersmann D
Xenobiotica; 1985; 15(8-9):735-41. PubMed ID: 4072261
[TBL] [Abstract][Full Text] [Related]
27. [Pharmacokinetics of Uromitexan].
Pohl J; Brock N; Schneider B; Wetzelsberger K
Methods Find Exp Clin Pharmacol; 1981; 3 Suppl 1():95S-101S. PubMed ID: 6798341
[No Abstract] [Full Text] [Related]
28. New mixed disulfides of L-cysteine derivatives and of glutathione with diethyldithiocarbamic acid and 2-mercaptoethanesulfonic acid.
Rajca A; Bertram B; Eisenbarth J; Wiessler M
Arzneimittelforschung; 1990 Mar; 40(3):282-6. PubMed ID: 2161235
[TBL] [Abstract][Full Text] [Related]
29. Does 2-mercaptoethane sulphonate (mesna) prevent cyclophosphamide and azathioprine induced immunosuppression? In vitro studies.
Al-Safi SA; Maddocks JL
Br J Clin Pharmacol; 1986 Mar; 21(3):267-70. PubMed ID: 2938613
[TBL] [Abstract][Full Text] [Related]
30. N-acetylcysteine and sodium 2-mercaptoethane sulfonate as sources of urinary thiol groups in the rat.
Ormstad K; Ohno Y
Cancer Res; 1984 Sep; 44(9):3797-800. PubMed ID: 6430554
[TBL] [Abstract][Full Text] [Related]
31. Analysis of BNP7787 thiol-disulfide exchange reactions in phosphate buffer and human plasma using microscale electrochemical high performance liquid chromatography.
Shanmugarajah D; Ding D; Huang Q; Chen X; Kochat H; Petluru PN; Ayala PY; Parker AR; Hausheer FH
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Apr; 877(10):857-66. PubMed ID: 19278906
[TBL] [Abstract][Full Text] [Related]
32. [Prevention of tumor formation in the bladder by sodium-2-mercaptoethane sulfonate (mesna). Experimental studies and clinical consequences].
Schmähl D; Habs M; Tacchi AM
Urologe A; 1984 Sep; 23(5):291-6. PubMed ID: 6438859
[TBL] [Abstract][Full Text] [Related]
33. Interaction of Mesna (2-mercaptoethane sulfonate) with the mutagenicity of cyclophosphamide in vitro and in vivo.
Lähdetie J; Räty R; Sorsa M
Mutat Res; 1990 Sep; 245(1):27-32. PubMed ID: 2118231
[TBL] [Abstract][Full Text] [Related]
34. New investigations into the stability of Mesna using LC-MS/MS and NMR.
Salman D; Swinden J; Peron JM; Barton S; Nabhani-Gebara S
Expert Rev Anticancer Ther; 2016; 16(1):123-30. PubMed ID: 26568378
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of BNP7787 and its metabolite mesna in plasma and ascites: a case report.
Verschraagen M; Boven E; Zegers I; Hausheer FH; Van der Vijgh WJ
Cancer Chemother Pharmacol; 2003 Jun; 51(6):525-9. PubMed ID: 12750838
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of rat hepatic microsomal lipid peroxidation by mesna via glutathione.
Bast A; Haenen GR; Savenije-Chapel EM
Arzneimittelforschung; 1987 Sep; 37(9):1043-5. PubMed ID: 3124863
[TBL] [Abstract][Full Text] [Related]
37. Quantification of BNP7787 (dimesna) and its metabolite mesna in human plasma and urine by high-performance liquid chromatography with electrochemical detection.
Verschraagen M; Zwiers TH; de Koning PE; Welink J; van der Vijgh WJ
J Chromatogr B Biomed Sci Appl; 2001 Apr; 753(2):293-302. PubMed ID: 11334343
[TBL] [Abstract][Full Text] [Related]
38. Simultaneous determination of BNP7787 and its metabolite mesna in plasma and tissue by micro-HPLC with a dual electrochemical detector.
Verschraagen M; Zwiers TH; Torun E; Donker MG; Reinhoud NJ; Van der Vijgh WJ
J Pharm Sci; 2003 May; 92(5):1040-50. PubMed ID: 12712424
[TBL] [Abstract][Full Text] [Related]
39. Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of human aminopeptidase N.
Hausheer FH; Parker AR; Petluru PN; Jair KW; Chen S; Huang Q; Chen X; Ayala PY; Shanmugarajah D; Kochat H
Cancer Chemother Pharmacol; 2011 Feb; 67(2):381-91. PubMed ID: 20440617
[TBL] [Abstract][Full Text] [Related]
40. The effect of sodium-2-mercaptoethane-sulphonate, N-acetylcysteine and cysteine on the uptake of cytosine arabinoside by normal and neoplastic thymus cells of mice.
Jastrzebski Z; Danysz A; Czyzewska-Szafran H; Czarnomska A
Arch Immunol Ther Exp (Warsz); 1988; 36(3):335-43. PubMed ID: 3150654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
